Ann: HER-Vaxx induced antibodies correlated with tumour reduction, page-18

Holy Moly - this is an impressive result.

IMU's team are certainly not sitting on their hands.

Conclusions drawn from the study include;
• HER-Vaxx treatment produced robust anti-HER-2-IgG* and IgG1 antibody
responses (p<0.001).
• HER-Vaxx-based vaccination of patients with HER-2 overexpressing
gastric/gastro-esophageal junction cancer (GC) induced anti-HER-2-IgG and IgG1
subclass antibody responses (p<0.001).
• HER-Vaxx induced antibodies correlated with tumour reduction (p=0.001)
• Compared to chemotherapy alone, the vaccination resulted in a statistically
significant overall survival benefit.
• The present data further validate the proof of concept for a first-in-class B-cell
immunotherapy based on HER-2/neu peptides.